Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
567 participants
OBSERVATIONAL
2017-09-01
2019-12-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Venous Distension in Patients With Aneurysmatic Arterial Disease
NCT02867501
Aortic Cross-Clamping and Systemic Inflammatory Response in Humans: Effect of Ischemic Preconditioning
NCT02570464
Medical & Economical Evaluation of Fenestrated & Branched Stent-grafts to Treat Complex Thoracal Abdominal Aneurysms
NCT01354821
Analysis of Respiration-induced Deformities of the Visceral and Renal Arteries Before and After Stenting
NCT04724863
Left Renal Vein Division for Juxtarenal Aortic Exposure
NCT05054972
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Arterial conduits in liver transplantation are almost as old as the procedure itself. First described by Starzl in 1984, the knowledge remains superficial. Although rarely performed, there is no doubt that thousands of patients' lives were saved because of the use of arterial grafts. However, arterial grafts are known to be associated with a higher rate of occlusion and a lower patient and graft survival when compared to conventional end-to-end anastomosis. In our recent retrospective study, the investigators showed that retransplantation procedure and aspirin in patients' medication are independent risk factors for the need of an arterial conduit. The investigators assume that aspirin could be a surrogate marker for vascular and metabolic status. Furthermore, in a meta-analysis the investigators found a four times higher occlusion rate compared to non-conduits.
Whether the site of conduit placement or certain types of material have an impact on occlusion and graft survival remains unknown. In addition, several studies discuss that antiaggregation or anticoagulation might be protective for occlusion of arterial conduits. Currently, there is no study that investigated this problem, most probably because of low case numbers.
STUDY OBJECTIVES
The primary goal of this study is to conduct a multicenter cohort analysis to define the outcome of different types of conduits and to investigate whether antiplatelet / anticoagulantion has an impact on patency rates.
1. Specific aim #1: To identify independent risk factors for early and late occlusion of arterial conduits in liver transplantation.
2. Specific aim #2: To compare different placement sites (infrarenal, supraceliac, iliacal, etc.) of arterial conduits in terms of occlusion rates and graft survival.
3. Specific aim #3: To investigate whether antiplatelet therapy is protective in terms of arterial patency.
STUDY DESIGN
This will be a multicenter single cohort study including only cases of deceased donor liver transplantation that required an aorto-hepatic or iliac-hepatic conduit for arterial reconstruction. Primary endpoint is 30-day conduit patency. Secondary endpoints include postoperative complications, death, late conduit occlusion, graft and patient survival.
SETTING
This multicenter cohort study will include several high-volume centers worldwide. Each participating center requires a prospective database from that data can be extracted. All consecutive cases of deceased donor liver transplantation requiring an arterial conduit from 1st of January 2007 until 31st of December 2016 are included allowing a minimum follow-up time of 6 months. Data collection at conduit4olt.org will be prospective, structured, anonymized, and encrypted.
INSTITUTIONAL REVIEW POLICY / ETHICAL POLICY
Each participating center is responsible to contact their local ethics committee and receive approval for participation, if applicable. For example, this project is considered as an audit in some countries and thus there is no need for formal approval in the form of a protocol submission.
ELIGIBILITY CRITERIA
Inclusion criteria:
* Liver transplantation requiring aorto-hepatic or iliac-hepatic conduits
* Deceased donor after brain death (DBD) or deceased donor after circulatory death (DCD)
* Whole organ as well as split allografts
* Primary liver transplantation as well as liver retransplantation
* Recipient age ≥18 years
Exclusion criteria:
* Living donor liver transplantation
* Pediatric liver transplantation (recipient age \<18 years)
* Arterial reconstruction other than aorto-hepatic or iliac-hepatic conduits
* Multivisceral transplantations
ESTIMATED SAMPLE SIZE
Each center should provide at least 30 cases that meet the inclusion criteria to allow adequate event rates for each outcome.
Statistical methods
The primary and secondary endpoints will be compared with patient and operation characteristics with univariate analysis. ROC Curve analysis will be performed to dichotomize continuous variables. Multivariable analysis (binary logistic and Cox regression) will be performed to identify independent risk factors. Statistical analysis will be performed using R Studio version 1.0.44 (RStudio, Inc. GNU Affero General Public License v3, Boston, MA, 2016) with the graphical user interface rBiostatistics.com beta version (rBiostatistics.com, Zurich, Switzerland, 2016, GNU License).
Christian E. Oberkofler Tim Reese Dimitri A. Raptis Henrik Petrowsky
On behalf of the conduit4olt.org team Swiss HPB Center, Department of Surgery and Transplantation, University Hospital Zurich, Switzerland
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
OTHER
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Aortohepatic Conduit
Placement of an interposition graft between hepatic artery and aorta during liver transplantation
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Deceased donor after brain death (DBD) or deceased donor after circulatory death (DCD)
* Whole organ as well as split allografts
* Primary liver transplantation as well as liver retransplantation
* Recipient age ≥18 years
Exclusion Criteria
* Pediatric liver transplantation (recipient age \<18 years)
* Arterial reconstruction other than aorto-hepatic or iliac-hepatic conduits
* Multivisceral transplantations
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Hospital Birmingham NHS Foundation Trust
OTHER
Medical University Innsbruck
OTHER
University of Bologna
OTHER
The Leeds Teaching Hospitals NHS Trust
OTHER
University of California, Los Angeles
OTHER
Johannes Gutenberg University Mainz
OTHER
Rennes University Hospital
OTHER
University of Lyon
OTHER
University of Rochester
OTHER
University of Southern California
OTHER
University of Zurich
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University Hospital Zurich
Zurich, , Switzerland
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2016-01889
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.